Results 31 to 40 of about 110,931 (189)

Bevacizumab in Ovarian Cancer

New England Journal of Medicine, 2012
N Engl J ...
Mehmet S, Copur, Angela M, Obermiller, Ryan, Ramaekers   +2 more
openaire   +5 more sources

Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Retinal Vein Occlusion [PDF]

, 2020
Purpose: Comparing the efficacy of intravitreal injections of bevacizumab to ranibizumab in the treatment of macular edema (ME) resulting from retinal vein occlusion (RVO).
Verbraak, F.D. (Frank), Schauwvlieghe, AME, Hoyng, C.B., Los, LI, Jong-Hesse, Y. de, Hoyng, CB, Vader, M.J.C. (Maartje J.C.), Leeuwen, R. (Redmer) van, Vingerling, Hans, Los, L.I. (Leonoor I.), Schlingemann, RO, Leeuwen, R. Van, van Leeuwen, R, Vingerling, J.R. (Hans), Dijkgraaf, M.G., de Jong-Hesse, Y, Schlingemann, R.O. (Reinier), Dijkman, G., Zwinderman, AH, Hoyng, C.B. (Carel), Lith-Verhoeven, J.J. van, Schlingemann, R.O., van Leeuwen, R., van Lith-Verhoeven, JJC, Vingerling, J.R., Vader, MJC, Verbraak, FD, Peto, T., de Jong-Hesse, Y. (Yvonne), Dijkman, G, Dijkgraaf, M.G.W. (Marcel), Los, L.I., Hooymans, JMM, Lith-Verhoeven, J.J.C. (Janneke) van, Schauwvlieghe, A.M., Schauwvlieghe, ASME, Verbraak, F.D., Zwinderman, A.H. (Ailko), Zwinderman, A.H., de Jong-Hesse, Y., Hooymans, J.M., Peto, T. (Tünde), Hooymans, JM, Vader, M.J.C., Hooymans, J.M.M. (Johanna), Peto, T, Dijkgraaf, MG, Schauwvlieghe, A.M.E. (Ann-Sofie), Dijkgraaf, MGW   +48 more
core   +3 more sources

A Comparative Parallel Study of Pharmacokinetics and Immunogenicity Following Single Intravenous Administration of Bevacizumab Biosimilar RPH-001 (Manufactured by R-Pharm Group, Russia) and Avastin® (Manufactured by F. Hoffmann-La Roche Ltd., Switzerland) in Healthy Male Volunteers

Разработка и регистрация лекарственных средств, 2019
Introduction. Bevacizumab is a monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab is used as a targeted monoor combination therapy for different solid tumors.
M. A. Kolganova, N. S. Bagaeva, Yu. V. Medvedev, I. E. Shohin, A. V. Demchinskaya, T. N. Palkina, D. A. Salazanov, G. E. Konopleva, M. S. Sheremeteva, Sh. Z. Archuadze, Ya. V. Lavrovsky, A. Yu. Savchenko, M. Yu. Samsonov   +12 more
doaj   +1 more source

Metformin alleviates bevacizumab-induced vascular endothelial injury in mice through growth differentiation factor 15 upregulation [PDF]

Iranian Journal of Basic Medical Sciences
Objective(s): Bevacizumab is a commonly used anticancer drug in clinical practice, but it often leads to adverse reactions such as vascular endothelial damage, hypertension, arterial and venous thrombosis, and bleeding.
Liqiang Chen, Yajuan Yin, Chunmiao Liu, Junying Liu, Mingqi Zheng, Yida Tang, Qing Yang, Jing Liu, Fan Chen, Lanbo Liu, Gang Liu   +10 more
doaj   +1 more source

Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces

MDM Policy & Practice, 2021
Background. Real-world evidence can be a valuable tool when clinical trial data are incomplete or uncertain. Bevacizumab was adopted as first-line therapy for metastatic colorectal cancer (mCRC) based on significant survival improvements in initial ...
Reka E. Pataky, Jaclyn Beca, David Tran, Wei Fang Dai, Erind Dvorani, Wanrudee Isaranuwatchai, Stuart Peacock, Riaz Alvi, Winson Y. Cheung, Craig C. Earle, Scott Gavura, Kelvin K. W. Chan   +11 more
doaj   +1 more source

Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma

Cancer Medicine, 2020
Introduction Bevacizumab has demonstrated activity in glioblastoma (GBM), but the true benefits and optimal dose‐schedule are debated. A lower dose‐schedule than standard‐dose bevacizumab (10 mg/kg 2‐weekly) might offer similar benefits with lower costs.
Jack Patrick Gleeson, Fergus Keane, Niamh M. Keegan, Emin Mammadov, Emily Harrold, Abdullah Alhusaini, Jeffrey Harte, Austin Eakin‐Love, Philip J. O'Halloran, Stephen MacNally, Bryan T. Hennessy, Oscar S. Breathnach, Liam Grogan, Patrick G. Morris   +13 more
doaj   +1 more source

Intravenous Bevacizumab Therapy in a Patient with Hereditary Hemorrhagic Telangiectasia, ENG E137K, Alcoholic Cirrhosis, and Portal Hypertension

Case Reports in Gastroenterology, 2017
Intravenous bevacizumab decreased mucosal bleeding in some patients with hereditary hemorrhagic telangiectasia (HHT). We treated a 47-year-old male who had HHT, severe epistaxis, and gastrointestinal bleeding, alcoholic cirrhosis, and portal hypertension
Luigi F. Bertoli, Pauline L. Lee, Lauren Lallone, James C. Barton   +3 more
doaj   +1 more source

Bevacizumab-induced tracheoesophageal fistula in a patient suffering from lung cancer with bulky subcarinal lymph node: a case report [PDF]

, 2018
2018-02A 66-year-old male with advanced non-small-cell lung cancer (NSCLC) who was previously treated with carboplatin, pemetrexed, and bevacizumab consequently suffered from severe coughing during degluti- tion. Chest computed tomography (CT) revealed a
Yasuo, Masanori, Urushihata, Kazuhisa, Kitaguchi, Yoshiaki, Yamamoto, Hiroshi, Ideura, Gen, Nishie, Kenichi, Kobayashi, Nobumitsu, Hanaoka, Masayuki, Ushiki, Atsuhito, Tateishi, Kazunari   +9 more
core   +1 more source

Evaluation of the association between bevacizumab concentration and clinical outcomes in patients with breast cancer brain metastasis

Heliyon
Bevacizumab is widely used in various clinical indications, but investigations into its optimal dosage for treating CNS metastases remain limited. The BEEP regimen, comprising bevacizumab, etoposide, and cisplatin, has recently demonstrated promising ...
Chih-Ning Cheng, Yun-Jung Tsai, Huai-Hsuan Chiu, Tom Wei-Wu Chen, Ching-Hung Lin, Yen-Sheng Lu, Ching-Hua Kuo   +6 more
doaj   +1 more source

A five arm natural history study of nasal vestibulitis

Cancer Medicine, 2023
Introduction Nasal symptoms are frequently reported by patients undergoing chemotherapy. Methods Eligible patients planning to receive paclitaxel, docetaxel, nab‐paclitaxel, bevacizumab without a concomitant taxane, or “other” (non‐taxane, non ...
Elizabeth J. Cathcart‐Rake, David Zahrieh, Deanne Smith, Susan Young, Shaylene McCue, Amanda O'Connor, Stephan Thomé, Mario Lacouture, Terra Register, Jill Piens, Bret B. Friday, Charles L. Loprinzi   +11 more
doaj   +1 more source